Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program

by: Iola Bonggay

The Food and Drug Administration, otherwise referred to as FDA, is a federal government agency operating within the United States Department of Health and Human Services that is primarily responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs.

The grants and programs of the FDA are all geared towards the achievement of its primary agency mission which is to "protect consumers and enhance public health by maximizing compliance of FDA regulated products and minimizing risk associated with those products."

In this capacity, the Food and Drug Administration has recently established the Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program in an attempt to study the effects of various physicochemical properties of ophthalmic suspensions and emulsions on ocular bioavailability.

To this effect, the program will cover the key physicochemical properties which may impact clearance, distribution, and drug release; specifically globule/particle size distribution, surface change, osmolality, pH, viscosity, and dispersibility.

It is known that there are several kinds of opthalmic drugs which are available in the market today. The goal of this study is to determine which manufacturing differences may result in physicochemical differences which in turn may affect clearance, distribution, and release of the drug.

  (continued...)

Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
  Page 2

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Core Clinical Centers for the Cardiothoracic Surgical Trials Network Program
In keeping with this mission, the National Institutes of Health has partnered with the Canadian Institutes of Health Research (CIHR), the National Heart, Lung, and Blood Institute (NHLBI), and the Institute of Circulatory and Respiratory Health (ICRH) to establish the Core Clinical Centers for the Cardiothoracic Surgical Trials Network Program.

---

Excellence in Hemoglobinopathies Research Award Program
The National Institutes of Health has formed a collaboration with the National Heart, Lung, and Blood Institute (NHLBI) in an effort to establish the Excellence in Hemoglobinopathies Research Award Program wherein both agencies have agreed to financially support the creation of studies that could potentially improve high-impact multi-disciplinary basic and translational research studies in the hemoglobinopathies.

---

Exploratory Clinical Trials for Small Business Grant Program
The National Institutes of Health has formed a partnership with the National Institute of Neurological Disorders and Stroke (NINDS) in order to establish the Exploratory Clinical Trials for Small Business Grant Program wherein they aim to establish a vehicle for Small Business Concerns (SBCs) in the process of submitting Small Business Technology Transfer (STTR) grant applications for exploratory clinical trials directly to the NIND

---

Medical Tropical Research Laboratory Program Infectious Disease Research Award
AFRIMS has recently announced the WRAIR Medical Tropical Research Laboratory Program(MTRLP) Infectious Disease Research Award(IDRA), a funding opportunity which solicits proposals that aim to tackle basic, preclinical and clinical research of emerging infectious diseases in Thailand and a certain region in Southeast Asia.

---